Illumina Contingent consideration fair value adjustments increased by 23.8% to -$16.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 45.5%, from -$11.00M to -$16.00M.
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
operating_business_combination_contingent_consideration__7f0be7| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$7.00M | $11.00M | -$49.00M | -$219.00M | -$1.00M | $29.00M | -$110.00M | $16.00M | -$271.00M | -$49.00M | -$11.00M | -$11.00M | -$21.00M | -$16.00M |
| QoQ Change | — | — | +257.1% | -545.5% | -346.9% | +99.5% | >999% | -479.3% | +114.5% | <-999% | +81.9% | +77.6% | +0.0% | -90.9% | +23.8% |
| YoY Change | — | — | — | — | <-999% | +98.0% | — | +49.8% | >999% | <-999% | +55.5% | — | -168.8% | +92.3% | -45.5% |